Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes

Cancer

Volumn 83, Issue 2, 1998, Pages 310-319

  Loman, Niklas ^a   Johannsson, Oskar ^a   Bendahl, Pär Ola ^a   Borg, Åke ^a   Fernö, Mårten ^a   Olsson, Håkan ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

BRCA1; BRCA2; Estrogen receptor; Hereditary breast carcinoma; Male breast carcinoma; Progesterone receptor

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; FEMALE; GENE MUTATION; HIGH RISK POPULATION; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT;

ADULT; BIOLOGICAL MARKERS; BREAST NEOPLASMS; BREAST NEOPLASMS, MALE; CARCINOMA; DISEASE SUSCEPTIBILITY; FEMALE; GENES, BRCA1; HUMANS; MALE; MIDDLE AGED; MUTATION; RECEPTORS, STEROID; RISK FACTORS;

EID: 0032528215     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W     Document Type: Article

References (49)

1. Claus E, Risch N, Thomson W. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet 1991;48:232-42.
2. Newman B, Austin M, Lee M, King M. Inheritance of human breast cancer: evidence for autosomal dominant transmission in high risk families. Proc Natl Acad Sci U S A 1988;85: 3044-8.
3. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266:66-71.
4. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995;378:789-92.
5. Tavtigian SV, Simmard J, Rommens J, Couch F, Shattuck-Eidens D, Neuhausen S, et al. The complete BRCA2 gene and mutations in chomosome 13q linked kindreds. Nat Genet 1996;12:333-7.
6. Stratton MR. Recent advances in understanding of genetic susceptibility to breast cancer. Hum Mol Genet 1996;5: 1515-9.
7. Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994;265: 2088-90.
8. Berman DB, Costalas J, Schultz DC, Grana G, Mary D, Godwin AK. A common mutation in BRCA2 that predisposes to a variety of cancers is found in both Jewish Ashkenazi and non-Jewish individuals. Cancer Res 1996;56:3409-14.
9. Friedman LS, Gayther SA, Kurosaki T, Gordon D, Noble B, Casey G, et al. Mutation analysis of BRCA1 and BRCA2 in a male breast cancer population. Am J Hum Genet 1997;60: 313-9.
10. Goldgar DE, Neuhausen SL, Steele L, Fields P, Ward JH, Tran T, et al. A 45-year follow-up of kindred 107 and the search for BRCA2. J Natl Cancer Inst Monogr 1995;17:15-9.
11. Johannesdottir G, Gudmundsson J, Bergthorsson JT, Arason A, Agnarsson BA, Eiriksdottir G, et al. High prevalence of the 999del5 mutation in Islandic breast and ovarian cancer patients. Cancer Res 1996;56:3663-5.
12. Struewing JP, Hartge P, Wackolder S, Baker SM, Berlin M, McAdams M, et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-8.
13. Szabo CI, King M-C. Population genetics of BRCA1 and BRCA2. Am J Hum Genet 1997;60:1013-20.
14. Malkin D, Li F, Strong L, Fraumeni J, Nelson C, Kim D, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250: 1233-8.
15. Li J, Yen C, Liaw D, Podyspanina K, Bose S, Wang SI, et al. PTEN, a putative protein tysosine phosphatase gene mutated in human brain, breast and prostate cancer. Science 1997;275:1943-7.
16. Steck PA, Pershouse MA, Jasser SA, Yung WKA, Lin H, Logon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997;16:356-62.
17. Hemmiki A, Tomlinson I, Markie D, Järvinen H, Sistonen P, Björkqvist A-M, et al. Localization of a susceptibility locus for Peutz-Jeghers syndrome using comparative genomic hybridization and targeted linkage analysis. Nat Genet 1997; 15:87-90.
18. Håkansson S, Johannsson O, Johansson U, Sellberg G, Loman N, Gerdes A-M, et al. Moderate frequency of BRCA1 and BRCA2 germ-line mutation in Scandinavian familial breast cancer. Am J Hum Genet 1997;60:1068-78.
19. Scully R, Chen J, Plug A, Xiao Y, Weaver D, Feunteun J, et al. Association of BRCA1 with Rad51 in miotic and meiotic cells. Cell 1997;88:265-75.
20. Scully R, Anderson SF, Chao DM, Wei W, Ye L, Young RA, et al. BRCA1 is a component of the RNA polymerase II holoenzyme. Proc Natl Acad Sci U S A 1997;94:5605-10.
21. Sharan SK, Morimatsu M, Albrechts U, Lim D-S, Regel E, Dinh C, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking BRCA2. Nature 1997;386:304-9.
22. Rajan J, Marquis S, Gardner H, Chodosh L. Developmental expression of BRCA2 colocalizes with BRCA1 and is associated with proliferation and differentiation in multiple tissues. Dev Biol 1997;184:385-401.
23. Tirkkonen M, Johannsson O, Agnarsson BA, Olsson H, Ingvarsson S, Karhu R, et al. Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. Cancer Res 1997;57:1222-7.
24. Johannsson OT, Idvall I, Anderson C, Borg Å, Egilsson V, Olsson H. Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 1997;33:362-71.
25. Breast Cancer Linkage Consortium. Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Lancet 1997;349:1505-10.
26. Habel LA, Stanford JL. Hormone receptors and breast cancer. Epidemiol Rev 1993;15:209-19.
27. Fernö M, Borg Å, Johansson U, Norgren A, Olsson H, Rydén S, et al. Estrogen and progesterone receptor analyses in more than 4000 human breast cancer samples. Acta Oncol 1990;29:129-35.
28. Hecht J, Winchester D. Male breast cancer. Am J Clin Pathol 1994;102:25-30.
29. Karp SE, Tonin PN, Bégin LR, Martinez JJ, Zhang JC, Pollak MN, et al. Influence of BRCA1 mutations on nuclear grade and estrogen receptor status of breast carcinoma in Ashkenazi women. Cancer 1997;80:435-41.
30. Fernö M, Borg Å, Sellberg G. Enzyme immunoassay of the estrogen receptor in breast cancer biopsy samples: a comparison with isoelectric focusing. Acta Radiol Oncol 1986;25: 171-5.
31. Norgren A, Borg Å, Fernö M, Johansson U, Lindahl B, Tsiobanelis K. Improved method for assay of estradiol and progesterone receptors with special reference to breast cancer. Anticancer Res 1982;2:315-20.
32. Fernö M, Borg Å, Johansson U. Enzyme immunoassay of progesterone receptor in breast cancer biopsy samples. Acta Oncol 1989;28:19-22.
33. Fernö M, Borg Å, Norgren A. A comparison of two steroid receptor assays in breast cancer: dextran coated charcoal and isoelectric focusing. Anticancer Res 1983;3:243-6.
34. Fernö M, Andersson C, Fallenius G, Idvall I. Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment. Acta Oncol 1996;35:17-22.
35. StataCorp. Stata Statistical Software. Version 5.0. College Station, TX: Stata Corporation, 1997.
36. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P, et al. Hereditary breast cancer pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996;77:697-709.
37. Tsai M-J, O'Malley BO. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu Rev Biochem 1994;63:451-86.
38. Clark GM, McGuire WL. Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 1988; 15:20-5.
39. Eisinger F, Stoppa-Lyonnet D, Longy M, Kerangueven F, Noguchi T, Bailly C, et al. Germ line mutation at BRCA1 affects the histoprognostic grade in hereditary breast cancer. Cancer Res 1996;56:471-4.
40. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996;335:1413-6.
41. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-70.
42. Johannsson OT, Ranstam J, Borg Å, Olsson H. Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. J Clin Oncol 1998;16: 397-404.
43. Brugarolas J, Jacks T. Double indemnity: p53, BRCA and cancer. Nat Med 1997;3:721-2.
44. Chapman MS, Verma IM. Transcriptional activation by BRCA1. Nature 1996;382:678-9.
45. Milner J, Ponder B, Hughes-Davies L, Seltmann M, Kouzarides T. Transcriptional activation functions in BRCA2. Nature 1997;386:772-3.
46. Spillman MA, Bowcock AM. BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to estrogen. Oncogene 1996;13:1639-45.
47. Vaughn JP, Cirisano FD, Huper G, Berchuck A, Futreal PA, Marks JR, et al. Cell cycle control of BRCA2. Cancer Res 1996;56:4590-4.
48. Marks JR, Hupers G, Vaughn JP, Davies PL, Norris J, McDonnel DP, et al. BRCA1 expression is not directly responsive to estrogen. Oncogene 1997;14:115-21.
49. Olsson H, Sigurdsson H, Borg A, Fernö M. Relationship of progesterone-receptor positivity in malignant breast tumors to reproductive status of women at tumor initiation: results from patients with possible radiation-induced tumors. J Natl Cancer Inst 1990;82:529-31.